SARS-CoV-2 Pneumonia Clinical Trial
Official title:
Macrophage Regulation of Ozone-Induced Lung Inflammation
The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.
Study participants will undergo a 1-day screening that includes a blood draw and breathing testing, return for a two-day series of testing to include blood draw, and brief breathing test before and after an inhaled challenge with either filtered air (FA) or ozone (O3). Participants return the next day for a brief breathing test, a blood draw and a procedure called bronchoscopy to evaluate the lung after the challenge. Participants then return 18 - 20 days later to repeat the two-day series of testing to be challenged with the exposure not received on the first series, (FA or O3). Each visit will take about 3 - 3.5 hours. Follow-up phone calls from the study team will occur at 24 hours after each 2-day test series. Total study duration is about one to one-and a half months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04382625 -
Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
|
Phase 4 | |
Enrolling by invitation |
NCT04602442 -
Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia
|
Phase 2 | |
Recruiting |
NCT04316949 -
Predictors of Respiratory Failure in SARS-Cov-2 Infection
|
||
Recruiting |
NCT04605757 -
Long-term Evolution of Pulmonary Involvement of Novel SARS-COV-2 Infection (COVID-19): Follow the Covid Study
|
||
Not yet recruiting |
NCT04405921 -
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19
|
Phase 3 | |
Completed |
NCT05465785 -
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
|
N/A | |
Completed |
NCT04491240 -
Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
|
Phase 1/Phase 2 |